Literature DB >> 30498705

Gastrointestinal Stromal Tumors.

Peter Hohenberger1, Michael Montemurro2, Chandrajit P Raut3,4,5, Piotr Rutkowski6.   

Abstract

Entities:  

Year:  2018        PMID: 30498705      PMCID: PMC6257142          DOI: 10.1159/000493934

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


× No keyword cloud information.
  13 in total

1.  Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

Authors:  Martin D McCarter; Cristina R Antonescu; Karla V Ballman; Robert G Maki; Peter W T Pisters; George D Demetri; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Linda McCall; David M Ota; Ronald P DeMatteo
Journal:  J Am Coll Surg       Date:  2012-07       Impact factor: 6.113

2.  Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.

Authors:  P Rutkowski; E Bylina; A Wozniak; Z I Nowecki; C Osuch; M Matlok; T Switaj; W Michej; M Wroński; S Głuszek; J Kroc; A Nasierowska-Guttmejer; H Joensuu
Journal:  Eur J Surg Oncol       Date:  2011-07-07       Impact factor: 4.424

3.  Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine.

Authors:  T Hølmebakk; B Bjerkehagen; K Boye; Ø Bruland; S Stoldt; K Sundby Hall
Journal:  Br J Surg       Date:  2016-03-14       Impact factor: 6.939

Review 4.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

Authors:  Heikki Joensuu; Aki Vehtari; Jaakko Riihimäki; Toshirou Nishida; Sonja E Steigen; Peter Brabec; Lukas Plank; Bengt Nilsson; Claudia Cirilli; Chiara Braconi; Andrea Bordoni; Magnus K Magnusson; Zdenek Linke; Jozef Sufliarsky; Massimo Federico; Jon G Jonasson; Angelo Paolo Dei Tos; Piotr Rutkowski
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

5.  Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).

Authors:  Peter Hohenberger; Burton Eisenberg
Journal:  Ann Surg Oncol       Date:  2010-04-21       Impact factor: 5.344

6.  Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.

Authors:  Heikki Joensuu; Mikael Eriksson; Juhani Collan; Marja H Balk; Serge Leyvraz; Michael Montemurro
Journal:  Radiother Oncol       Date:  2015-07-27       Impact factor: 6.280

7.  Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.

Authors:  Piotr Rutkowski; Alessandro Gronchi; Peter Hohenberger; Sylvie Bonvalot; Patrick Schöffski; Sebastian Bauer; Elena Fumagalli; Pawel Nyckowski; Buu-Phuc Nguyen; Jan Martijn Kerst; Marco Fiore; Elzbieta Bylina; Mathias Hoiczyk; Annemieke Cats; Paolo G Casali; Axel Le Cesne; Jürgen Treckmann; Eberhard Stoeckle; Johannes H W de Wilt; Stefan Sleijfer; Ronald Tielen; Winette van der Graaf; Cornelis Verhoef; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2013-06-13       Impact factor: 5.344

8.  Tumor rupture during surgery for gastrointestinal stromal tumors: pay attention!

Authors:  Nadia Peparini; Piero Chirletti
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

9.  Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group.

Authors:  Thanh-Khoa Huynh; Pierre Meeus; Philippe Cassier; Olivier Bouché; Sophie Lardière-Deguelte; Antoine Adenis; Thierry André; Julien Mancini; Olivier Collard; Michael Montemurro; Emmanuelle Bompas; Maria Rios; Nicolas Isambert; Didier Cupissol; Jean-Yves Blay; Florence Duffaud
Journal:  BMC Cancer       Date:  2014-03-05       Impact factor: 4.430

10.  Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Jörg T Hartmann; Daniel Pink; Jochen Schütte; Giuliano Ramadori; Peter Hohenberger; Justus Duyster; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Maarit Sarlomo-Rikala; Bengt Nilsson; Harri Sihto; Karla V Ballman; Mika Leinonen; Ronald P DeMatteo; Peter Reichardt
Journal:  Cancer       Date:  2014-04-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.